MA38076A1 - Dérivés d'oxazolidin-2-one-pyrimidine - Google Patents

Dérivés d'oxazolidin-2-one-pyrimidine

Info

Publication number
MA38076A1
MA38076A1 MA38076A MA38076A MA38076A1 MA 38076 A1 MA38076 A1 MA 38076A1 MA 38076 A MA38076 A MA 38076A MA 38076 A MA38076 A MA 38076A MA 38076 A1 MA38076 A1 MA 38076A1
Authority
MA
Morocco
Prior art keywords
oxazolidin
pyrimidine derivatives
pi3k
phosphatidylinositol
kinase
Prior art date
Application number
MA38076A
Other languages
English (en)
French (fr)
Inventor
Heinrich Rueeger
Pascal Furet
Andreas Lerchner
Robin Alec Fairhurst
Frank Stephan Kalthoff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38076A1 publication Critical patent/MA38076A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA38076A 2012-11-12 2013-11-11 Dérivés d'oxazolidin-2-one-pyrimidine MA38076A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725113P 2012-11-12 2012-11-12
PCT/IB2013/060052 WO2014072956A1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MA38076A1 true MA38076A1 (fr) 2018-02-28

Family

ID=49667527

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38076A MA38076A1 (fr) 2012-11-12 2013-11-11 Dérivés d'oxazolidin-2-one-pyrimidine

Country Status (42)

Country Link
US (3) US9296733B2 (OSRAM)
EP (2) EP2922848B1 (OSRAM)
JP (1) JP6262245B2 (OSRAM)
KR (1) KR102153763B1 (OSRAM)
CN (1) CN104718204B (OSRAM)
AP (1) AP2015008347A0 (OSRAM)
AR (1) AR093408A1 (OSRAM)
AU (1) AU2013343022B2 (OSRAM)
BR (1) BR112015010136A2 (OSRAM)
CA (1) CA2890942C (OSRAM)
CL (1) CL2015001202A1 (OSRAM)
CO (1) CO7380758A2 (OSRAM)
CR (1) CR20150248A (OSRAM)
CU (1) CU24365B1 (OSRAM)
CY (1) CY1119391T1 (OSRAM)
DK (1) DK2922848T5 (OSRAM)
EA (2) EA029714B1 (OSRAM)
EC (1) ECSP15025093A (OSRAM)
ES (1) ES2641820T3 (OSRAM)
HR (1) HRP20171425T1 (OSRAM)
HU (1) HUE034492T2 (OSRAM)
IL (1) IL238239A (OSRAM)
IN (1) IN2015DN02912A (OSRAM)
JO (1) JO3334B1 (OSRAM)
LT (1) LT2922848T (OSRAM)
MA (1) MA38076A1 (OSRAM)
MX (1) MX363436B (OSRAM)
MY (1) MY174239A (OSRAM)
NZ (1) NZ706591A (OSRAM)
PE (1) PE20151006A1 (OSRAM)
PH (1) PH12015501053B1 (OSRAM)
PL (1) PL2922848T3 (OSRAM)
PT (1) PT2922848T (OSRAM)
RS (1) RS56336B1 (OSRAM)
SG (1) SG11201503447QA (OSRAM)
SI (1) SI2922848T1 (OSRAM)
TN (1) TN2015000120A1 (OSRAM)
TW (1) TWI608005B (OSRAM)
UA (1) UA114001C2 (OSRAM)
UY (1) UY35128A (OSRAM)
WO (1) WO2014072956A1 (OSRAM)
ZA (1) ZA201502175B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111503C2 (uk) 2011-09-27 2016-05-10 Новартіс Аг 3-піримідин-4-іл-оксазолідин-2-они як інгібітори мутантної idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
GEP201706699B (en) 2013-03-14 2017-07-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN115645534A (zh) 2015-09-24 2023-01-31 德雷克塞尔大学 治疗或预防皮肤障碍的新型组合物和方法
RU2018140001A (ru) 2016-05-18 2020-06-18 Пикур Терапьютикс Аг Лечение повреждений кожи
WO2017198347A1 (en) * 2016-05-18 2017-11-23 Piqur Therapeutics Ag Treatment of skin lesions
TW201929861A (zh) 2017-11-06 2019-08-01 瑞士商諾華公司 包含㗁唑啶-2-酮-嘧啶衍生物之調配物
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
EP4518911A1 (en) 2022-05-02 2025-03-12 Precirix N.V. Pre-targeting

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921149B1 (OSRAM) 1970-12-28 1974-05-30
JPS4921148B1 (OSRAM) 1970-12-28 1974-05-30
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (en) 1988-02-25 1989-08-30 Merck & Co. Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE69120221T2 (de) 1990-07-03 1996-11-21 Mitsui Petrochemical Ind Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz
AU692090B2 (en) 1995-04-13 1998-05-28 Taiho Pharmaceutical Co., Ltd. Novel 4,6-diarylpyrimidine derivatives and salts thereof
JP3734907B2 (ja) 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
CN1129597C (zh) 1997-07-24 2003-12-03 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤剂
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
PT930302E (pt) 1998-01-16 2003-07-31 Hoffmann La Roche Derivados de benzo-sulfona
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
EP1144390A2 (en) 1999-01-22 2001-10-17 Amgen Inc., Kinase inhibitors
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
JP2003505384A (ja) 1999-07-15 2003-02-12 ファーマコピーア，インコーポレーティッド ブラジキニンｂ１受容体アンタゴニスト
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
JP5074653B2 (ja) 2000-03-29 2012-11-14 サイクラセル リミテッド ２−置換４−ヘテロアリール−ピリミジンおよび増殖性障害におけるその使用
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
CN1657523A (zh) 2000-04-28 2005-08-24 田边制药株式会社 环状化合物
JP2004501913A (ja) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
EP1317433A2 (en) 2000-09-06 2003-06-11 Chiron Corporation Inhibitors of glycogen synthase kinase 3
KR20030032035A (ko) 2000-09-15 2003-04-23 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
MXPA03005610A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
CA2448626A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
EP1397142A4 (en) 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE60332433D1 (de) 2002-03-15 2010-06-17 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
ES2289279T3 (es) 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
US7179826B2 (en) 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
CA2499497A1 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
JP2006515274A (ja) 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
JP2006521357A (ja) 2003-03-24 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
AU2004230928B2 (en) 2003-04-09 2010-12-02 Exelixis, Inc. Tie-2 modulators and methods of use
US20060229308A1 (en) 2003-07-15 2006-10-12 Neurogen Corporation Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands
US7566712B2 (en) 2003-07-16 2009-07-28 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
CA2587642C (en) * 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
CN101080401A (zh) 2004-12-13 2007-11-28 神经能质公司 经取代的二芳基类似物
WO2006065872A1 (en) 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
EP1836169B9 (en) 2004-12-28 2012-07-04 Kinex Pharmaceuticals, LLC Compositions and methods of treating cell proliferation disorders
EP1838703A2 (en) 2005-01-19 2007-10-03 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
KR20070108916A (ko) 2005-02-25 2007-11-13 쿠도스 파마슈티칼스 리미티드 Ｍｔｏｒ 억제제로서 작용하는 하이드라지노메틸,하이드라조노메틸 및 5-원 복소환 화합물 및 이의항암제로서의 용도
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
BRPI0706395A2 (pt) 2006-01-11 2011-03-22 Astrazeneca Ab composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007120897A2 (en) * 2006-04-13 2007-10-25 The Trustees Of Columbia University In The City Of New York Compositions and intraluminal devices for inhibiting vascular stenosis
AR064571A1 (es) 2006-12-28 2009-04-08 Basf Ag Pirimidinas sustituidas en posicion 2 por heterociclos nitrogenados, medicamentos y composiciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del cancer.
MX2009008341A (es) 2007-02-06 2009-08-12 Novartis Ag Inhibidores de cinasa de pi3 y metodos para su uso.
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
CN101801962A (zh) 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖疾病的三取代嘧啶衍生物
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
RU2496500C2 (ru) 2008-03-05 2013-10-27 Новартис Аг Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr
MX338088B (es) 2008-03-26 2016-04-01 Novartis Ag Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
US8575338B2 (en) 2008-04-09 2013-11-05 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
BRPI0921802A8 (pt) 2008-10-31 2018-03-13 Novartis Ag uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
JP5747440B2 (ja) 2009-02-06 2015-07-15 住友化学株式会社 ヒドラジド化合物及びその有害生物防除用途
US8673891B2 (en) 2009-02-06 2014-03-18 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
CN102438993A (zh) 2009-05-19 2012-05-02 陶氏益农公司 用于控制真菌的化合物和方法
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
TWI499592B (zh) 2009-09-09 2015-09-11 Avila Therapeutics Inc Ｐｉ３激酶抑制劑及其用途
JP5967827B2 (ja) 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012009678A1 (en) 2010-07-16 2012-01-19 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their method of use
ES2699951T3 (es) 2010-10-01 2019-02-13 Novartis Ag Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina, un inhibidor PIK3
NZ734152A (en) 2010-10-18 2019-03-29 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
BR112013020159A2 (pt) 2011-02-11 2016-11-08 Dana Farber Cancer Inst Inc método para inibir células tumorais de hamartoma
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
KR20140059786A (ko) 2011-09-01 2014-05-16 노파르티스 아게 골암의 치료에 사용하기 위한 또는 골 내로의 원발성 암 세포의 전이성 파종을 예방하기 위한 pi3k 억제제
UA111503C2 (uk) 2011-09-27 2016-05-10 Новартіс Аг 3-піримідин-4-іл-оксазолідин-2-они як інгібітори мутантної idh
CA2851082A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
MX360892B (es) * 2012-05-16 2018-11-20 Novartis Ag Régimen de dosificación para un inhibidor de cinasa pi-3.
MX2014014969A (es) 2012-06-06 2015-03-13 Novartis Ag Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral.
US20150216870A1 (en) 2012-08-16 2015-08-06 Novartis Ag Combination of PI3K Inhibitor and C-Met Inhibitor
WO2014064058A1 (en) 2012-10-23 2014-05-01 Novartis Ag Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EP2970242B1 (en) 2013-03-14 2017-09-06 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
GEP201706699B (en) 2013-03-14 2017-07-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN103483345B (zh) 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
CN103694218B (zh) 2013-12-05 2016-04-27 中山大学 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用

Also Published As

Publication number Publication date
EA029714B1 (ru) 2018-05-31
CA2890942A1 (en) 2014-05-15
CN104718204A (zh) 2015-06-17
ZA201502175B (en) 2018-05-30
ES2641820T3 (es) 2017-11-14
TW201427974A (zh) 2014-07-16
SI2922848T1 (sl) 2017-10-30
PL2922848T3 (pl) 2017-12-29
JP6262245B2 (ja) 2018-01-17
CN104718204B (zh) 2017-11-28
US20140135330A1 (en) 2014-05-15
WO2014072956A1 (en) 2014-05-15
UY35128A (es) 2014-06-30
LT2922848T (lt) 2017-09-25
DK2922848T5 (en) 2017-10-30
HUE034492T2 (en) 2018-02-28
RS56336B1 (sr) 2017-12-29
SG11201503447QA (en) 2015-05-28
ECSP15025093A (es) 2019-03-29
HK1209108A1 (en) 2016-03-24
IN2015DN02912A (OSRAM) 2015-09-11
AR093408A1 (es) 2015-06-03
HRP20171425T1 (hr) 2017-11-17
CY1119391T1 (el) 2018-02-14
BR112015010136A2 (pt) 2017-07-11
EP3199158B1 (en) 2019-04-17
EA201590929A1 (ru) 2015-08-31
EA027987B1 (ru) 2017-09-29
JP2015536974A (ja) 2015-12-24
PH12015501053A1 (en) 2015-07-27
PH12015501053B1 (en) 2015-07-27
PT2922848T (pt) 2017-10-05
AU2013343022B2 (en) 2015-08-20
US20190382399A1 (en) 2019-12-19
TWI608005B (zh) 2017-12-11
MY174239A (en) 2020-04-01
EP3199158A1 (en) 2017-08-02
EP2922848B1 (en) 2017-06-28
CO7380758A2 (es) 2015-09-10
CL2015001202A1 (es) 2015-07-03
AU2013343022A1 (en) 2015-04-23
PE20151006A1 (es) 2015-07-04
IL238239A (en) 2017-05-29
EA201790289A1 (ru) 2017-06-30
KR102153763B1 (ko) 2020-09-09
US10202371B2 (en) 2019-02-12
CU24365B1 (es) 2018-10-04
US9296733B2 (en) 2016-03-29
CR20150248A (es) 2015-07-01
KR20150082295A (ko) 2015-07-15
DK2922848T3 (da) 2017-10-09
EP2922848A1 (en) 2015-09-30
MX2015005914A (es) 2015-09-08
MX363436B (es) 2019-03-22
CU20150050A7 (es) 2015-11-27
NZ706591A (en) 2016-03-31
TN2015000120A1 (en) 2016-06-29
CA2890942C (en) 2021-01-12
AP2015008347A0 (en) 2015-04-30
US20160168145A1 (en) 2016-06-16
UA114001C2 (xx) 2017-04-10
JO3334B1 (ar) 2019-03-13

Similar Documents

Publication Publication Date Title
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
MA42376A (fr) Dérivés d'oxopyridine substitués
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MA44474B1 (fr) Inhibiteurs de la ferroportine
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
PH12014501900A1 (en) Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
MA35894B1 (fr) Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k
FR3042191B1 (fr) Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives
MA38451A1 (fr) Benzoimidazol-2-ylpyrimidines modulatrices du récepteur de l'histamine h4
MA39719B1 (fr) Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine
TN2014000340A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
MA38838B1 (fr) Dérivés de pipéridinyl-indole et leur utilisation en tant qu'inhibiteurs du facteur b du complément
FR2985256B1 (fr) Derives piperazinyles pour le traitement de cancers
MA39118A1 (fr) Quinazoline-thf-amines utilisées en tant qu'inhibiteurs de la pde1